These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19175532)

  • 1. Intersecting guidelines: administering erythropoiesis-stimulating agents to chronic kidney disease patients with cancer.
    Bennett CL; Becker PS; Kraut EH; Samaras AT; West DP
    Semin Dial; 2009; 22(1):1-4. PubMed ID: 19175532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of erythropoiesis-stimulating agents in the treatment of anemia.
    Fishbane S
    Am J Manag Care; 2010 Mar; 16 Suppl Issues():S67-73. PubMed ID: 20297874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revisiting the treatment of anemia in the setting of chronic kidney disease, hematologic malignancies, and cancer: perspectives with opinion and commentary.
    Musio F
    Expert Rev Hematol; 2020 Nov; 13(11):1175-1188. PubMed ID: 33028115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?
    Bormanis J; Quirt I; Chang J; Kouroukis CT; MacDonald D; Melosky B; Verma S; Couture F
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):132-9. PubMed ID: 23357249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
    Nowrousian MR; Dunst J; Vaupel P
    Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoiesis-stimulating agents in chronic kidney disease: what have we learned in 25 years?
    Hung SC; Lin YP; Tarng DC
    J Formos Med Assoc; 2014 Jan; 113(1):3-10. PubMed ID: 24090633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is nephrology more at ease than oncology with erythropoiesis-stimulating agents? Treatment guidelines and an update on benefits and risks.
    Locatelli F; Gascón P
    Oncologist; 2009; 14 Suppl 1():57-62. PubMed ID: 19762517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended administration of erythropoiesis-stimulating agents for optimising the management of renal anaemia: what is the evidence?
    Roger SD
    Int J Clin Pract; 2008 Sep; 62(9):1413-22. PubMed ID: 18793377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoiesis-stimulating agents in oncology.
    Glaspy JA
    J Natl Compr Canc Netw; 2008 Jul; 6(6):565-75. PubMed ID: 18597710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoiesis-stimulating agents, hypertension and left ventricular hypertrophy in the chronic kidney disease patient.
    Schmid H; Schiffl H; Lederer SR
    Curr Opin Nephrol Hypertens; 2011 Sep; 20(5):465-70. PubMed ID: 21738032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of anemia in patients with solid tumors receiving chemotherapy in palliative setting: usual practice versus guidelines.
    de Putter R; Geboes K; De Man M; Van Belle S
    Acta Clin Belg; 2018 Aug; 73(4):251-256. PubMed ID: 29336240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of chemotherapy-induced anemia].
    Kadokura G; Katsumata N
    Gan To Kagaku Ryoho; 2014 Apr; 41(4):416-20. PubMed ID: 24743356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoiesis-stimulating agents for anemic patients with cancer.
    Sheikh S; Littlewood TJ
    Expert Rev Hematol; 2010 Dec; 3(6):697-704. PubMed ID: 21091146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoiesis-stimulating agents in anemia: use and misuse.
    Dharmarajan TS; Widjaja D
    J Am Med Dir Assoc; 2009 Nov; 10(9):607-16. PubMed ID: 19883882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anemia management in cancer patients with chronic kidney disease.
    Latcha S
    Semin Dial; 2019 Nov; 32(6):513-519. PubMed ID: 31596520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
    Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
    Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peginesatide: a potential erythropoiesis stimulating agent for the treatment of anemia of chronic renal failure.
    Doss S; Schiller B
    Nephrol Nurs J; 2010; 37(6):617-26. PubMed ID: 21290916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving regulatory landscape with erythropoiesis-stimulating agents and impact on managed care.
    Fatodu H
    Am J Manag Care; 2010 Mar; 16 Suppl Issues():S74-9. PubMed ID: 20297875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.
    Aapro MS; Link H
    Oncologist; 2008; 13 Suppl 3():33-6. PubMed ID: 18458123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.